Notícias Corporativas Archives

FarmaMondo achieved the reimbursement for Carbaglu (Carglumic Acid) in Hong Kong.

Dezembro 20, 2024

FarmaMondo Hong Kong Limited confirms the approval of the reimbursement for Carbaglu (Carglumic Acid) dispersible tablets, on behalf of Recordati Rare Diseases in Hong Kong.

Farma Mondo Hong Kong Ltd. and Recordati UK Ltd. sign exclusive license and distribution agreement for Qarziba® in Hong Kong

Agosto 28, 2024Julho 15, 2024

Farma Mondo announces the signing with Recordati UK Ltd. (a Recordati Rare Diseases Company) of an exclusive License and Distribution Agreement in Hong Kong for Qarziba® (dinutuximab beta)

FarmaMondo Group and HRA Pharma Rare Diseases Sign Exclusive Partnership to Distribute Lysodren (Mitotane) in Brazil

Julho 4, 2024Julho 4, 2024

CHIASSO, Switzerland and Châtillon, France – June 21, 2024 – Farma Mondo Group, a Swiss-based pharmaceutical company, and HRA Pharma Rare Diseases, are pleased to announce the signing of an Exclusive Distribution Agreement for the supply of Lysodren (Mitotane) in Brazil.

FarmaMondo Group and Stemline Therapeutics B.V. sign exclusive partnership to grant access to Elacestrant

Julho 19, 2024Março 1, 2024

Farma Mondo Group and Stemline Therapeutics B.V. sign exclusive partnership to grant access to Elacestrant through Named Patient Supplies to patients in certain Countries where the product is not licensed or not commercially available.

Dompé farmaceutici and FarmaMondo Group extend their Distribution Partnership for Oxervate®

Julho 4, 2024Junho 1, 2023

MILAN, ITALY and CHIASSO, SWITZERLAND, June 1, 2023 – Dompé farmaceutici S.p.A. (“Dompé”) and FarmaMondo Group announced they have extended their agreement whereby FarmaMondo Group becomes Dompé’s distribution partner for Oxervate (cenegermin) in additional selected countries.

FarmaMondo Group signs exclusive partnership to commercialize QRX003 for Netherton Syndrome in Singapore

Julho 4, 2024Julho 28, 2023

Chiasso, Switzerland and Ashburn, US – 28th July, 2023 – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, announces today the signing of a licensing and distribution agreement with Quoin Pharmaceuticals Inc. for exclusive rights to commercialize QRX003 in Singapore.

FarmaMondo at BIO BOSTON 5-8 June 2023

Abril 17, 2023

How to bring innovative therapies to patients in growth and emerging markets is a real challenge for medium and small biotechnology companies. FarmaMondo has a

Advisory Board in Hong Kong

Abril 13, 2023

Homozygous Familial Hypercholesterolemia (HoFH) is a rare life-threatening genetic disorder characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C) in the blood and premature